The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant attention within the British Isles, prompting a notable shift in peptide trends. Availability these medications remains a complex challenge , with NHS provision currently limited and specialist practices offering therapy at a higher cost . Question